JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com -- Trinity Biotech plc (NASDAQ:TRIB) stock surged 73% after the company announced it received regulatory approval from the New York State Department of Health for its PreClara™ Ratio biomarker test for preeclampsia risk assessment.
The FDA-cleared test will be provided through Trinity’s New York reference laboratory, with service rollout planned for the third quarter of 2025. The approval represents a significant milestone in the company’s maternal health strategy and strengthens its position in the U.S. diagnostics market.
The PreClara™ test provides clinicians with information to support decision-making for patients hospitalized with hypertensive disorders of pregnancy, which affect approximately 500,000 women annually in the United States. These disorders are a leading cause of maternal and neonatal complications.
According to recent U.S.-based studies published in March 2025, incorporating the test into standard care could potentially generate neonatal cost savings exceeding $10 million per 1,000 patients, primarily through reduced preterm deliveries and NICU admissions.
The regulatory approval also establishes groundwork for the anticipated commercial introduction of PrePsia™, Trinity Biotech’s proprietary preeclampsia risk assessment technology designed for use in early pregnancy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.